356046-26-9

Basic information

• Product Name: 3,6,9,12,15-PENTAOXAHEPTADECANE-1,17-DIYL BIS-AZIDE
• Synonyms: 3,6,9,12,15-PENTAOXAHEPTADECANE-1,17-DIYL BIS-AZIDE;1,17-diazido-;Azido-PEG6-azide;Azido-PEG5-Azide;N3-PEG5-N3;1,17-Diazido-3,6,9,12,15-pentaoxaheptadecane;1-azido-2-[2-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethane
• CAS NO: 356046-26-9
• Molecular Formula: C₁₂H₂₄N₆O₅
• Molecular Weight: 332.36
• Product Categories: Nitric Oxide Reagents;Cross Linking Reagents
• Mol File: 356046-26-9.mol
• Article Data: 39

Chemical Properties

• Appearance: /
• Density: 1.13194 g/mL
• Refractive Index: n/D 1.4716
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• Stability: Moisture Sensitive
• CAS DataBase Reference: 3,6,9,12,15-PENTAOXAHEPTADECANE-1,17-DIYL BIS-AZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,6,9,12,15-PENTAOXAHEPTADECANE-1,17-DIYL BIS-AZIDE(356046-26-9)
• EPA Substance Registry System: 3,6,9,12,15-PENTAOXAHEPTADECANE-1,17-DIYL BIS-AZIDE(356046-26-9)

Safety Data

• Hazardous Substances Data: 356046-26-9(Hazardous Substances Data)

Usage

Chemical Properties

Clear Colourless Oil

Uses

Different sources of media describe the Uses of 356046-26-9 differently. You can refer to the following data:
1. A cross-linking reagent
2. A cross-linking reagent.

InChI:InChI=1/C12H24N6O5/c13-17-15-1-3-19-5-7-21-9-11-23-12-10-22-8-6-20-4-2-16-18-14/h1-12H2

Upstream product

• 139115-90-5 2-(2-azidoethoxy)ethanol 
• 7460-82-4 diethylene glycol ditosylate 
• 2615-15-8 pentaethylene glycol 
• 124-63-0 methanesulfonyl chloride 
• 98-59-9 p-toluenesulfonyl chloride 
• 42749-27-9 hexa(ethyleneglycol) ditosylate 
• 109789-40-4 3,6,9,12,15-pentaoxaheptadecane-1,17-diyl dimethanesulfonate 

Downstream Products

• 189209-27-6 tert-butyl N-[2-[2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy] ethoxy]ethoxy]ethyl]carbamate 
• 1356146-69-4 N-[9-(2-[(2'-azido-2-oxo-6,9,12,15,18-pentaoxa-3-azaicos-1-yl)(1-methylethyl)carbamoyl]phenyl)-6-(diethylamino)-3H-xanthen-3-ylidene]-N-ethylethanaminium chloride 
• 1356146-64-9 N-(17-azido-3,6,9,12,15-pentaoxaheptadec-1-yl)-N₂-(1-methyl-ethyl)-N₂-([2-(2,3,6,7,12,13,16,17-octahydro-1H,5H,11H,15H-pyrido[3,2,1-ij]quinolizino[1',9':6,7,8]chromeno[2,3-f]quinolin-4-ium-9-yl)phenyl]carbonyl)glycinamide chloride 

Relevant articles and documents

Transferrin-Appended Nanocaplet for Transcellular siRNA Delivery into Deep Tissues

Transferrin (Tf) is known to induce transcytosis, which is a consecutive endocytosis/exocytosis event. We developed a Tf-appended nanocaplet (TfNC?siRNA) for the purpose of realizing siRNA delivery into deep tissues and RNA interference (RNAi)

Design and Synthesis of Oleanolic Acid Trimers to Enhance Inhibition of Influenza Virus Entry

Influenza is a major threat to millions of people worldwide. Entry inhibitors are of particular interest for the development of novel therapeutic strategies for influenza. We have previously discovered oleanolic acid (OA) to be a mild influenza hemagglutinin (HA) inhibitor. In this work, inspired by the 3D structure of HA as a homotrimeric receptor, we designed and synthesized 15 OA trimers with different linkers and central region via the copper-catalyzed azide-alkyne cycloaddition reaction. All of the OA trimers were evaluated for their antiviral activities in vitro, and 12c, 12e, 13c, and 13d were observed to exhibit robust potency (IC50 in the submicromolar range) against influenza A/WSN/33 (H1N1) virus that was stronger than that observed with oseltamivir. In addition, these compounds also displayed strong biological activity against A/Hong Kong/4801/2014 and B/Sichuan/531/2018 (BV). The results of hemagglutination inhibition assays and surface plasmon resonance binding assays suggest that these OA trimers may interrupt the interaction between the HA protein of influenza virus and the host cell sialic acid receptor, thus blocking viral entry. These findings highlight the utility of multivalent OA conjugates to enhance the ligand-target interactions in anti-influenza virus drug design and are also helpful for studying antiviral drugs derived from natural products.

MONOMER AND MULTIMERIC ANTI-HBV AGENTS

The present invention is directed to compounds, compositions and methods for preventing, treating or curing hepatitis B (HBV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment, prevention or eradication of HBV infection.